ArticleCancer medicine2026
Fluorescent Multiplex Immunohistochemistry (mIHC) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor-Infiltrating Immune Cells and Predicted the Clinical Outcome.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) remains heterogeneous. The real-world efficacy and comparison of triplet regimens against doublet regimens is unclear. Moreover, the immunological mechanisms underlying differential responses to NAC are poorly understood. This study aimed to compare the efficacy of doublet versus triplet NAC in a Chinese LAGC cohort, and characterize the post-treatment tumor immune microenvironment (TIME) to identify immune correlates of response and survival.
methodsThis retrospective study enrolled patients with locally advanced gastric cancer (GC) who received NAC followed by D2 gastrectomy. The clinical outcomes of patients treated with different NAC regimens were analyzed. The TIME was further characterized using fluorescent multiplex immunohistochemistry (mIHC) to analyze the density and spatial proximity of the immune cells the SOX regimen group.
resultsA total of 141 GC patients with complete survival data were included in the final analysis. The overall efficacy of NAC was consistent with prior reports: 7.8% (11/141) achieved ypT0, 36.2% (51/141) achieved ypN0, and 6.4% (9/141) attained a pathological complete response (pCR). Triplet regimens did not provide a statistically significant survival and response advantage over doublet regimens. mIHC analysis showed longer DFS were consistently associated with higher densities of effector immune cells and lower densities of exhausted/immunosuppressive subsets. Favorable survival was also linked to a closer spatial proximity of CD68
conclusionThis study confirms the consistent anticancer efficacy of neoadjuvant chemotherapy in LAGC. To better inform individualized post-NAC treatment strategies, analysis of the TIME using multiplex mIHC on surgical specimens is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.